Fig. 2

Effect of ACA, Rapa and 17aE2 treatments on liver MEK1 signaling in liver. A Representative western blots for phospho-MEK1 at Ser217 (pMEK1) and total levels of MEK1 protein in liver samples from young untreated (Y), old untreated (O), and old mice treated with ACA or Rapa (O, early and late treatments). B Representative western blots for pMEK1 and MEK1 effects of 17aE2 (early and late) treatments separated by sex (males = M, females = F). C Bar graphs represent the mean ± SEM of pMEK1 ratios and MEK1 protein levels in liver samples obtained from 16 young and 16 old mice plus, at least, 8 mice for each of the ACA and Rapa treatments groups. Data for 17aE2 were obtained from 8 young males and 8 young females, 8 old males and 8 old female mice, while treatments represent a minimum of 4 mice for each treatment and sex group. All values have been normalized to young control females as described in the Methods section. The (*) indicates statistical significance (p < 0.05) in a t-test between the indicated pair of groups